Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Additional screening criteria check may apply for qualification. Inclusion Criteria: * 1\. Subjects provided written informed consent to participate. * 2\. Male and female subjects with a confirmed diagnosis of EPP based on medical history, aged 18 years to 75 years, inclusive, at Screening. * 3\. Subjects are willing and able to travel to the study sites for all scheduled visits. * 4\. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel). Exclusion Criteria: * 1\. History or presence of photodermatoses other than EPP. * 2\. Subjects who are unwilling or unable to go outside during daylight hours (e.g., between 1 hour post sunrise and 1 hour pre-sunset) during the study. * 3\. Presence of clinically significant hepatobiliary disease based on LFT values at Screening. * 4\. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin \>1.5 × ULN at Screening. * 5\. Subjects with or having a history (in the last 2 years) of excessive alcohol intake in the opinion of the Investigator. * 6\. History or presence of melanoma and/or atypical nevus at Screening. * 7\. History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child). * 8\. History or presence of pre-malignant skin lesion squamous cell carcinoma, basal cell carcinoma,…